Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SNURI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
OBI-999
|
|||||
| Synonyms |
OBI-999; OBI999
Click to Show/Hide
|
|||||
| Organization |
OBI Pharma (Originator);Contino Biotech
|
|||||
| Drug Status |
Phase 1/2 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
OBI-888
|
Antibody Info | ||||
| Antigen Name |
Globo H (globotriaosylceramide)
|
Antigen Info | ||||
| Payload Name |
MMAE
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
ThioBridge-PEG24-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) | 3 | ug/mL |
Mean pharmacokinetic parameters of first cycle of OB-999, the dose of ADC is 0.4 mg/kg.
|
[1], [2] |
| Area Under the Concentration-Time Curve (AUC) | 2.9 | day*ug/mL |
Mean pharmacokinetic parameters of first cycle of OB-999, the dose of ADC is 0.4 mg/kg.
|
[1], [2] |
| Time to Maximum Concentration (Tmax) | 0.06 | day |
Mean PK parameters of OBI-999 following first cycle, 0.4 mg/kg.
|
[2] |
| Maximum Observed Concentration (Cmax) | 3 | ug/mL |
Mean PK parameters of OBI-999 following first cycle, 0.4 mg/kg.
|
[2] |
| Area Under the Concentration-Time Curve (AUC) | 2.9 | day*ug/mL |
Mean PK parameters of OBI-999 following first cycle, 0.4 mg/kg, AUCinf.
|
[2] |
| Time to Maximum Concentration (Tmax) | 0.06 | day |
Mean PK parameters of OBI-999 following first cycle, 0.8 mg/kg.
|
[2] |
| Maximum Observed Concentration (Cmax) | 6.7 | ug/mL |
Mean PK parameters of OBI-999 following first cycle, 0.8 mg/kg.
|
[2] |
| Area Under the Concentration-Time Curve (AUC) | 9.2 | day*ug/mL |
Mean PK parameters of OBI-999 following first cycle, 0.8 mg/kg, AUCinf.
|
[2] |
| Time to Maximum Concentration (Tmax) | 0.06 | day |
Mean PK parameters of OBI-999 following first cycle, 1.2 mg/kg.
|
[2] |
| Maximum Observed Concentration (Cmax) | 12.1 | ug/mL |
Mean PK parameters of OBI-999 following first cycle, 1.2 mg/kg.
|
[2] |
| Area Under the Concentration-Time Curve (AUC) | 19.1 | day*ug/mL |
Mean PK parameters of OBI-999 following first cycle, 1.2 mg/kg, AUCinf.
|
[2] |
| Time to Maximum Concentration (Tmax) | 0.06 | day |
Mean PK parameters of OBI-999 following first cycle, 1.6 mg/kg.
|
[2] |
| Maximum Observed Concentration (Cmax) | 22.3 | ug/mL |
Mean PK parameters of OBI-999 following first cycle, 1.6 mg/kg.
|
[2] |
| Area Under the Concentration-Time Curve (AUC) | 40.9 | day*ug/mL |
Mean PK parameters of OBI-999 following first cycle, 1.6 mg/kg, AUCinf.
|
[2] |
Distribution
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Volume of Distribution (Vd) | 10.8 | L |
Mean pharmacokinetic parameters of first cycle of OB-999, the dose of ADC is 0.4 mg/kg.
|
[1], [2] |
| Area Under the Concentration-Time Curve (AUC) | 2.9 | day*ug/mL |
Mean pharmacokinetic parameters of first cycle of OB-999, the dose of ADC is 0.4 mg/kg.
|
[1], [2] |
| Area Under the Concentration-Time Curve (AUC) | 2.9 | day*ug/mL |
Mean PK parameters of OBI-999 following first cycle, 0.4 mg/kg, AUCinf.
|
[2] |
| Volume of Distribution (Vd) | 10.8 | L |
Mean PK parameters of OBI-999 following first cycle, 0.4 mg/kg.
|
[2] |
| Area Under the Concentration-Time Curve (AUC) | 9.2 | day*ug/mL |
Mean PK parameters of OBI-999 following first cycle, 0.8 mg/kg, AUCinf.
|
[2] |
| Volume of Distribution (Vd) | 10.9 | L |
Mean PK parameters of OBI-999 following first cycle, 0.8 mg/kg.
|
[2] |
| Area Under the Concentration-Time Curve (AUC) | 19.1 | day*ug/mL |
Mean PK parameters of OBI-999 following first cycle, 1.2 mg/kg, AUCinf.
|
[2] |
| Volume of Distribution (Vd) | 9 | L |
Mean PK parameters of OBI-999 following first cycle, 1.2 mg/kg.
|
[2] |
| Area Under the Concentration-Time Curve (AUC) | 40.9 | day*ug/mL |
Mean PK parameters of OBI-999 following first cycle, 1.6 mg/kg, AUCinf.
|
[2] |
| Volume of Distribution (Vd) | 9.5 | L |
Mean PK parameters of OBI-999 following first cycle, 1.6 mg/kg.
|
[2] |
Metabolism
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 2.9 | day*ug/mL |
Mean pharmacokinetic parameters of first cycle of OB-999, the dose of ADC is 0.4 mg/kg.
|
[1], [2] |
| Area Under the Concentration-Time Curve (AUC) | 2.9 | day*ug/mL |
Mean PK parameters of OBI-999 following first cycle, 0.4 mg/kg, AUCinf.
|
[2] |
| Area Under the Concentration-Time Curve (AUC) | 9.2 | day*ug/mL |
Mean PK parameters of OBI-999 following first cycle, 0.8 mg/kg, AUCinf.
|
[2] |
| Area Under the Concentration-Time Curve (AUC) | 19.1 | day*ug/mL |
Mean PK parameters of OBI-999 following first cycle, 1.2 mg/kg, AUCinf.
|
[2] |
| Area Under the Concentration-Time Curve (AUC) | 40.9 | day*ug/mL |
Mean PK parameters of OBI-999 following first cycle, 1.6 mg/kg, AUCinf.
|
[2] |
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Clearance (CL) | 10.6 | L/day |
Mean pharmacokinetic parameters of first cycle of OB-999, the dose of ADC is 0.4 mg/kg.
|
[1], [2] |
| Elimination Half-Life (t1/2) | 0.72 | day |
Mean pharmacokinetic parameters of first cycle of OB-999, the dose of ADC is 0.4 mg/kg.
|
[1], [2] |
| Area Under the Concentration-Time Curve (AUC) | 2.9 | day*ug/mL |
Mean pharmacokinetic parameters of first cycle of OB-999, the dose of ADC is 0.4 mg/kg.
|
[1], [2] |
| Area Under the Concentration-Time Curve (AUC) | 2.9 | day*ug/mL |
Mean PK parameters of OBI-999 following first cycle, 0.4 mg/kg, AUCinf.
|
[2] |
| Elimination Half-Life (t1/2) | 0.72 | day |
Mean PK parameters of OBI-999 following first cycle, 0.4 mg/kg.
|
[2] |
| Clearance (CL) | 10.6 | L/day |
Mean PK parameters of OBI-999 following first cycle, 0.4 mg/kg.
|
[2] |
| Area Under the Concentration-Time Curve (AUC) | 9.2 | day*ug/mL |
Mean PK parameters of OBI-999 following first cycle, 0.8 mg/kg, AUCinf.
|
[2] |
| Elimination Half-Life (t1/2) | 1.37 | day |
Mean PK parameters of OBI-999 following first cycle, 0.8 mg/kg.
|
[2] |
| Clearance (CL) | 7.5 | L/day |
Mean PK parameters of OBI-999 following first cycle, 0.8 mg/kg.
|
[2] |
| Area Under the Concentration-Time Curve (AUC) | 19.1 | day*ug/mL |
Mean PK parameters of OBI-999 following first cycle, 1.2 mg/kg, AUCinf.
|
[2] |
| Elimination Half-Life (t1/2) | 1.79 | day |
Mean PK parameters of OBI-999 following first cycle, 1.2 mg/kg.
|
[2] |
| Clearance (CL) | 4.2 | L/day |
Mean PK parameters of OBI-999 following first cycle, 1.2 mg/kg.
|
[2] |
| Area Under the Concentration-Time Curve (AUC) | 40.9 | day*ug/mL |
Mean PK parameters of OBI-999 following first cycle, 1.6 mg/kg, AUCinf.
|
[2] |
| Elimination Half-Life (t1/2) | 1.96 | day |
Mean PK parameters of OBI-999 following first cycle, 1.6 mg/kg.
|
[2] |
| Clearance (CL) | 4 | L/day |
Mean PK parameters of OBI-999 following first cycle, 1.6 mg/kg.
|
[2] |
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
≈ 70.7
|
%
|
MDA-MB-231 cells
HCC1428 cells |
Breast adenocarcinoma
Breast adenocarcinoma |
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Patients Enrolled |
Advanced solid tumors that had been previously treated with standard-of-care therapy and their physicians had determined that such therapy was no longer effective, or patients had declined to receive further standard-of-care treatments.
|
||||
| Administration Dosage |
The starting dose of 0.40 mg/kg on day 1 of each 21-day cycle; A standard 3 + 3 dose-escalation design was used, and doses of 0.80, 1.20, and 1.60 mg/kg were also administered on day 1 of each 21-day cycle; intravenous infusion over 60 minutes.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04084366 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1/2, open-label, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI-999 in patients with advanced solid tumors. | ||||
| Primary Endpoint |
The incidence of dose-limiting toxicities and adverse events and determination of the maximum tolerated dose (MTD)/recommended phase II dose.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [6] | ||||
| Patients Enrolled |
Inclusion criteria require patients aged ≥18 with advanced solid tumors (refractory to/intolerant of standard therapy), measurable disease (RECIST 1.1), ECOG 0-1, adequate organ function (ALT/AST ≤3×ULN [≤5×ULN if liver mets], bilirubin ≤1.5×ULN, ANC ≥1,500/uL, platelets ≥100,000/uL), and Globo H H-score ≥100 (Cohort-Expansion). HIV/HBV/HCV-infected patients are eligible if controlled. Exclusions include recent chemotherapy/radiation (<3 weeks), major surgery (<28 days), Grade ≥2 neuropathy, prior Globo H-targeted therapy, uncontrolled CNS metastases, cardiac dysfunction, or concurrent prohibited medications.
Click to Show/Hide
|
||||
| Administration Dosage |
Part A: Five cohorts at escalating dose levels 0.4, 0.8, 1.2, 1.6 and 2.0 mg/kg (capping calculations at a maximum at 100 kg) of OBI-999 liquid form via IV infusion to establish maximum tolerated dose (MTD) and Recommended phase 2 dose (RP2D).Part B: Five cohorts of patients at RP2D of OBI-999 liquid form, as determined from Part A, via IV infusion.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04084366 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-999 in Patients with Advanced Solid Tumors | ||||
| Primary Endpoint |
The primary objective is to assess the clinical benefit of OBI-999 through Objective Response Rate (ORR: CR+PR) per RECIST 1.1, evaluated every 6 weeks (±7 days) during initial 3 months, then every 9 weeks (±7 days) until treatment discontinuation, progression, death, or new therapy initiation-whichever occurs first within ~2 years (up to 35 cycles).
Click to Show/Hide
|
||||
| Other Endpoint |
Key secondary endpoints include preliminary efficacy (ORR, Clinical Benefit Rate [CBR], Duration of Response [DOR], PFS per RECIST 1.1) and immunogenicity (anti-drug antibodies [ADAs]), analyzed from Week 1 to Week 106. Pharmacokinetics (PK) of OBI-999 and its active metabolite (MMAE) will be assessed via non-compartmental methods during Cycles 1-2, measuring Cmax, AUC, t1/2, clearance (Cl), Tmax, and volume of distribution (Vd).
Click to Show/Hide
|
||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 34% | Positive Globo H expression (Globo H+++/++) | ||
| Method Description |
Mice were treated with an intravenous dose of the ADCs at 0.3 mg/kg, qw*6.
|
||||
| In Vivo Model | MCF-7 CDX model | ||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 60% | Positive Globo H expression (Globo H+++/++) | ||
| Method Description |
Mice were treated with an intravenous dose of the ADCs at 1 mg/kg, qw*6.
|
||||
| In Vivo Model | MCF-7 CDX model | ||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 83% | Positive Globo H expression (Globo H+++/++) | ||
| Method Description |
Mice were treated with an intravenous dose of the ADCs at 1 mg/kg, qw*4.
|
||||
| In Vivo Model | NCI-N87 CDX model | ||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 85% | Positive Globo H expression (Globo H+++/++) | ||
| Method Description |
Mice were treated with an intravenous dose of the ADCs at 10 mg/kg, qw*4.
|
||||
| In Vivo Model | NCI-H526 CDX model | ||||
| In Vitro Model | Lung small cell carcinoma | NCI-H526 cells | CVCL_1569 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 95% | Positive Globo H expression (Globo H+++/++) | ||
| Method Description |
Mice were treated with an intravenous dose of the ADCs at 10 mg/kg, qw*2.
|
||||
| In Vivo Model | MCF-7 CDX model | ||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97% | Positive Globo H expression (Globo H+++/++) | ||
| Method Description |
Mice were treated with an intravenous dose of the ADCs at 10 mg/kg, qw*4.
|
||||
| In Vivo Model | NCI-N87 CDX model | ||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97% | Positive Globo H expression (Globo H+++/++) | ||
| Method Description |
Mice were treated with an intravenous dose of the ADCs at 1-3 mg/kg, qw*4.
|
||||
| In Vivo Model | NCI-N87 CDX model | ||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98% | Positive Globo H expression (Globo H+++/++) | ||
| Method Description |
Mice were treated with an intravenous dose of the ADCs at 3 mg/kg, qw*6.
|
||||
| In Vivo Model | MCF-7 CDX model | ||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99% | Positive Globo H expression (Globo H+++/++) | ||
| Method Description |
Mice were treated with an intravenous dose of the ADCs at 10 mg/kg, qw*4.
|
||||
| In Vivo Model | HPAC CDX model | ||||
| In Vitro Model | Pancreatic adenocarcinoma | HPAC cells | CVCL_3517 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [5] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 70.70% | |||
| Method Description |
In vivo , In each animal study,the antitumor efficacy was evaluated with doses of 1.00, 3.00, or 10.00 mg/kg of OBI-999 via i.v. injection. In NCI-N87 xenograft model,treatment groups of MMAE 0.191 mg/kg and Ctrl-ADC 3 mg/kg were also included. Each study utilized 6 to 8 mice per group.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
| Breast adenocarcinoma | HCC1428 cells | CVCL_1252 | |||
References